NGM Biopharmaceuticals, Inc.
NASDAQ: NGM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David J. Woodhouse
- Employees
- 138
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $128.5M
- Website
- https://www.ngmbio.com
Loading NGM…
Loading profile data…Frequently asked questions about NGM
What does NGM Biopharmaceuticals, Inc. (NGM) do?
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently...
Where does NGM trade?
NGM Biopharmaceuticals, Inc. (NGM) trades on the NASDAQ Global Select.
What sector is NGM in?
NGM Biopharmaceuticals, Inc. (NGM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NGM Biopharmaceuticals, Inc.?
David J. Woodhouse is the chief executive officer of NGM Biopharmaceuticals, Inc. (NGM).
Where is NGM Biopharmaceuticals, Inc. headquartered?
NGM Biopharmaceuticals, Inc. is headquartered in United States.
Does NGM pay a dividend?
NGM Biopharmaceuticals, Inc. (NGM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NGM go public?
NGM Biopharmaceuticals, Inc. (NGM) completed its initial public offering in 2019.